Plasma Renin Activity: How to Interpret Your Result

What Plasma Renin Activity Actually Measures

PRA quantifies the enzymatic rate at which renin cleaves angiotensinogen to produce angiotensin I in a blood sample over a set incubation period. The result is reported in nanograms of angiotensin I generated per milliliter per hour (ng/mL/hr). This is not the same as a direct renin concentration (DRC) assay, which counts renin molecules rather than measuring enzymatic output 1.

Renin is released by the juxtaglomerular cells of the kidney in response to three stimuli: reduced renal perfusion pressure, decreased sodium delivery to the macula densa, and sympathetic nervous system activation. Once angiotensin I forms, angiotensin-converting enzyme (ACE) in the lungs converts it to angiotensin II, which raises blood pressure directly and triggers aldosterone secretion from the adrenal cortex 2.

The distinction between PRA and DRC matters clinically. PRA depends on both the amount of renin protein and the availability of its substrate, angiotensinogen. Patients on estrogen therapy or oral contraceptives have elevated angiotensinogen levels, which can artificially inflate PRA without a true increase in renin secretion 3. The 2016 Endocrine Society Clinical Practice Guideline notes that DRC may be preferable in estrogen-treated patients for this reason, though most U.S. laboratories still default to PRA 1.

Normal Ranges and Why They Shift

A typical reference range for upright (ambulatory) PRA is 0.25 to 5.82 ng/mL/hr, while supine values run lower at roughly 0.15 to 2.33 ng/mL/hr. These numbers vary between laboratories and assay platforms. Age, sodium intake, posture, time of day, and kidney function all move the needle 4.

Posture produces the single largest physiological swing. Standing upright for two hours can raise PRA two to four fold compared to a supine draw because gravity reduces renal perfusion and the sympathetic nervous system activates baroreceptor-mediated renin release 2. A high-sodium diet suppresses renin; a low-sodium diet or volume depletion stimulates it. Circadian rhythm matters too. PRA peaks in the early morning hours and dips in the afternoon, which is why most guidelines recommend a mid-morning draw after the patient has been upright for at least two hours 1.

Aging also compresses renin output. Healthy adults older than 65 have PRA values that average 40 to 60% lower than younger adults, partially explaining why low-renin hypertension is more common in older populations 5.

High PRA: What It Signals

An elevated PRA tells you the kidneys are calling for more angiotensin. That call can be appropriate or pathological.

Appropriate (secondary) elevations occur during volume depletion, hemorrhage, heart failure, cirrhosis with ascites, or diuretic use. The kidneys sense low perfusion and ramp up renin to restore blood pressure. In these settings, both renin and aldosterone rise in tandem 2.

Pathological high-renin states include renovascular hypertension, renin-secreting tumors (rare, accounting for fewer than 0.1% of hypertension cases), and malignant hypertension. In renovascular hypertension, stenosis of a renal artery reduces perfusion to that kidney, triggering unilateral renin hypersecretion. A 2014 meta-analysis of renal artery stenosis prevalence found that atherosclerotic renovascular disease explains 1 to 5% of all hypertension cases, with higher rates in patients with resistant hypertension 6.

Dr. John Funder, lead author of the Endocrine Society primary aldosteronism guideline, has stated: "A suppressed aldosterone in the face of markedly elevated PRA points toward renovascular disease or a salt-losing nephropathy, not primary aldosteronism" 1. High PRA with low aldosterone can also indicate adrenal insufficiency or congenital adrenal hyperplasia affecting the zona glomerulosa.

Medications frequently raise PRA. ACE inhibitors and ARBs block downstream feedback, so renin rises compensatorily. Diuretics contract volume. These drugs should ideally be withdrawn (with appropriate substitution) for at least two to four weeks before diagnostic testing for primary aldosteronism 1.

Low PRA: The Primary Aldosteronism Flag

A suppressed PRA (typically <0.25 ng/mL/hr in the upright position) is the hallmark of mineralocorticoid excess. The most common cause is primary aldosteronism (PA), a condition in which one or both adrenal glands produce too much aldosterone independent of the renin-angiotensin system 1.

PA is not rare. A prospective study across five Italian centers (PAPY Study, N=1,125 newly diagnosed hypertensives) found PA in 11.2% of participants 7. The Endocrine Society guideline recommends screening in all patients with sustained blood pressure above 150/100 mmHg, resistant hypertension (uncontrolled on three drugs), hypertension with spontaneous or diuretic-induced hypokalemia, hypertension with an adrenal incidentaloma, or hypertension with a family history of early-onset hypertension or stroke before age 40 1.

Other low-renin conditions include Liddle syndrome, apparent mineralocorticoid excess, congenital adrenal hyperplasia (11-beta-hydroxylase or 17-alpha-hydroxylase deficiency), and chronic licorice ingestion. Low-renin essential hypertension is also common, found in roughly 25 to 30% of patients with primary hypertension, particularly in Black patients and older adults. This subset responds better to calcium channel blockers and thiazide diuretics than to ACE inhibitors or ARBs 8.

The Aldosterone-to-Renin Ratio: How Clinicians Use PRA in Practice

The single most common reason your doctor orders a PRA is to calculate the aldosterone-to-renin ratio (ARR). The 2016 Endocrine Society guideline defines a positive screen as an ARR above 30 (ng/dL per ng/mL/hr) with a concurrent plasma aldosterone concentration (PAC) of at least 10 ng/dL 1.

The ARR is a screening test, not a diagnosis. A positive screen requires confirmatory testing with one of four accepted protocols: oral sodium loading (3-day high-sodium diet followed by 24-hour urine aldosterone collection), intravenous saline infusion (2 liters of 0.9% NaCl over 4 hours), fludrocortisone suppression (0.1 mg every 6 hours for 4 days), or captopril challenge (25 to 50 mg orally with serial blood sampling) 1.

The guideline's authors write: "The ARR is highly sensitive but has limited specificity; confirmatory testing is mandatory before proceeding to subtype classification with adrenal CT and, when indicated, adrenal venous sampling" 1.

PRA values very close to zero can inflate the ARR dramatically. If your PRA is 0.1 ng/mL/hr and your aldosterone is 8 ng/dL, the ratio is 80, but the absolute aldosterone is not particularly high. This is why the dual criterion (ratio plus minimum aldosterone) exists. Some laboratories now report DRC rather than PRA, which uses different ARR cutoffs (typically above 3.7 when DRC is measured in mU/L and aldosterone in ng/dL) 9.

Pre-Test Preparation: Getting an Accurate PRA

Sample integrity for PRA is fragile. Several controllable variables can produce misleading results.

Medication washout. The Endocrine Society recommends stopping mineralocorticoid receptor antagonists (spironolactone, eplerenone) for at least four weeks and stopping beta-blockers, central alpha-agonists, NSAIDs, ACE inhibitors, ARBs, and dihydropyridine calcium channel blockers for at least two weeks before the ARR screening draw. If blood pressure management is needed during this washout, verapamil sustained-release (with or without hydralazine) and alpha-blockers (doxazosin, prazosin) have the least effect on the ARR 1.

Posture protocol. The patient should be out of bed for at least two hours, seated for 5 to 15 minutes before the draw.

Sodium status. Unrestricted sodium intake is recommended; a very low-sodium diet stimulates renin and can mask a suppressed PRA. Some protocols check a 24-hour urine sodium to confirm adequate intake (target above 100 mEq/day) 1.

Potassium correction. Hypokalemia suppresses aldosterone secretion and can produce a false-negative ARR. Potassium should be repleted to at least 4.0 mEq/L before testing 10.

Sample handling. Blood collected for PRA should be placed immediately on ice and centrifuged within 30 minutes. Room temperature storage allows ongoing angiotensin I generation in vitro, falsely raising results.

How to Lower Elevated Plasma Renin Activity

The strategy depends on the cause. In secondary elevations, treat the underlying volume deficit or remove the offending medication. In renovascular hypertension, revascularization (angioplasty with or without stenting) can reduce renin-driven hypertension, though the CORAL trial (N=947) showed that stenting added to optimal medical therapy did not significantly reduce cardiovascular events compared with medical therapy alone 11.

Pharmacologically, renin suppression follows a predictable hierarchy. Direct renin inhibitors (aliskiren 150 to 300 mg daily) reduce PRA by 50 to 80% 12. Beta-blockers suppress renin release from juxtaglomerular cells and reduce PRA by approximately 50%. Sodium supplementation (under medical supervision for specific salt-wasting conditions) reduces the renal stimulus for renin. ACE inhibitors and ARBs paradoxically raise PRA because they interrupt the angiotensin II negative feedback loop, so they are not used when the goal is PRA reduction itself 2.

Dietary sodium restriction below 2,300 mg/day, while beneficial for blood pressure, will raise PRA as a normal compensatory response. This is physiologically expected, not harmful.

How to Raise Suppressed Plasma Renin Activity

A truly suppressed PRA from primary aldosteronism is not something you "raise" with lifestyle changes. The fix is treating the aldosterone excess. For unilateral aldosterone-producing adenomas, laparoscopic adrenalectomy cures or improves hypertension in 50 to 70% of patients 13. For bilateral adrenal hyperplasia or patients who are not surgical candidates, spironolactone (12.5 to 50 mg daily as starting dose, titrated up to 400 mg if needed) or eplerenone (25 to 50 mg twice daily) provides mineralocorticoid blockade 1.

After successful adrenalectomy for a unilateral adenoma, PRA typically normalizes within weeks. Post-surgical monitoring at 6 and 12 weeks should include both aldosterone and PRA to confirm biochemical cure 14.

For patients whose suppressed PRA reflects low-renin essential hypertension rather than PA, no intervention to "fix" the renin is needed. Treatment selection simply shifts toward thiazide diuretics and calcium channel blockers, which work better in low-renin physiology than RAAS-blocking agents 8.

When to Repeat Testing

A single abnormal ARR screen does not lock in a diagnosis. The Endocrine Society recommends repeating the ARR if the initial result is borderline (ratio 20 to 30), if medication washout was incomplete, or if clinical suspicion remains high despite a negative initial screen 1. After treatment (surgery or MRA therapy), PRA and aldosterone should be rechecked at 3, 6, and 12 months to assess response. A post-adrenalectomy PRA that remains suppressed with elevated aldosterone suggests residual contralateral disease or incomplete resection.

For patients on long-term spironolactone for bilateral adrenal hyperplasia, annual monitoring of PRA, aldosterone, potassium, and renal function is standard practice. Spironolactone doses above 100 mg/day carry significant risk of gynecomastia (reported in up to 52% of men in one series), prompting many clinicians to switch to eplerenone despite its shorter half-life and higher cost 15.